Emcure Pharmaceuticals has announced the re-appointment of three independent directors for their second consecutive terms, following a board meeting held on February 04, 2026. The decision was made based on recommendations from the company's Nomination and Remuneration Committee and is subject to shareholder approval.

Board Approvals and Appointments

The board of directors approved the re-appointment of three key independent directors during the meeting that commenced at 12:40 p.m. (IST) and concluded at 1:15 p.m. (IST). All three directors have been serving the company since April 16, 2021, and are being re-appointed for their second consecutive terms.

Director Profiles and Experience

Dr. Shailesh Kripalu Ayyangar brings over 40 years of experience in healthcare, with deep expertise in pharmaceutical R&D, biologicals, pharmaceutical operations, animal health, and consumer healthcare. He previously served as a member of Sanofi's International Leadership Team and Country Chair for India & South Asia, building the business to become one of the most respected and fast-growing multinational companies in the region. Dr. Ayyangar holds a bachelor's degree in veterinary science and animal husbandry from Gujarat Agricultural University and a post-graduate diploma in management from the Indian Institute of Management, Ahmedabad.

Mr. Vijay Keshav Gokhale holds a master's degree in history and joined the Indian Foreign Service in 1981. His distinguished diplomatic career includes postings in Hong Kong, Hanoi, Beijing, and New York. He served in various senior positions including Secretary (Finance), Director (China & East Asia), High Commissioner to Malaysia (January 2010 to October 2013), Ambassador to Germany (October 2013 to January 2016), Ambassador to China (January 2016 to October 2017), and Foreign Secretary (January 2018 to January 2020).

Dr. Vidya Rajiv Yeravdekar serves as the Principal Director of Symbiosis Society and Pro Chancellor of Symbiosis International University. She has been appointed as a member of the expert group on Global Outreach of Higher Education by UGC to implement the National Education Policy 2020 and serves as a member of the Advisory Group of Analytical and Advisory work (ASA) at the World Bank. Dr. Yeravdekar holds an MBBS degree, a bachelor's degree in law from the University of Pune, and a PhD in internationalization of higher education in India from Symbiosis International University.

Regulatory Compliance

The company confirmed that all three directors are not debarred from holding director positions by SEBI or any other authority, in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018, and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018. Additionally, none of the directors are related to any existing directors or key managerial personnel of the company. The appointments comply with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Emcure Pharmaceuticals has delivered exceptional financial performance in the third quarter, demonstrating strong growth across all key financial metrics. The pharmaceutical company showcased impressive operational efficiency with significant improvements in revenue generation, profitability, and operational leverage compared to the corresponding period in the previous year.

Comprehensive Financial Performance

The company's consolidated financial results reveal substantial growth across multiple parameters during the quarter. Revenue, profit, and EBITDA figures indicate strong operational performance and effective business execution by the management team.

Strong Revenue Growth Momentum

Emcure Pharmaceuticals achieved notable revenue growth of 20.41% year-on-year, with quarterly revenue increasing from ₹19.60 billion to ₹23.60 billion. This solid top-line growth demonstrates the company's ability to expand its market presence and effectively capitalize on business opportunities in the pharmaceutical sector.

The revenue expansion reflects strong demand for the company's pharmaceutical products and successful market penetration strategies. This consistent growth trajectory indicates robust business fundamentals and effective commercial execution.

Exceptional EBITDA Performance

The company's operational efficiency was particularly noteworthy, with EBITDA surging 38.87% from ₹3.55 billion to ₹4.93 billion. More importantly, the EBITDA margin expanded significantly to 20.85% from 18.07% in the previous year, representing a substantial improvement of 278 basis points.

This margin expansion demonstrates the company's ability to generate higher operational leverage and improved cost efficiency, indicating strong pricing power and effective operational management across business segments.

Outstanding Profitability Enhancement

The company's bottom-line performance was equally impressive, with consolidated net profit surging 49.35% from ₹1.54 billion to ₹2.30 billion. This substantial profit growth outpaced revenue growth, indicating improved operational efficiency and enhanced overall financial performance.

The strong profitability metrics, combined with robust EBITDA performance, suggest effective cost management and operational leverage, positioning Emcure Pharmaceuticals favorably for sustained financial performance and enhanced shareholder returns.

Market Position Strengthening

The comprehensive quarterly results highlight the company's operational strength and its ability to deliver consistent financial performance across all key metrics. The combination of solid revenue growth, exceptional EBITDA expansion, and outstanding profit growth positions Emcure Pharmaceuticals competitively in the pharmaceutical market.

This strong financial performance reflects the company's focus on operational excellence and strategic business development, contributing to enhanced market confidence and strengthened growth prospects in the competitive pharmaceutical industry.